Karyopharm Therapeutics (NASDAQ:KPTI) received a $18.00 price target from research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 71.27% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday. BidaskClub downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. ValuEngine downgraded shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. assumed coverage on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $17.33.

Shares of Karyopharm Therapeutics (KPTI) traded down $0.60 during midday trading on Tuesday, reaching $10.51. 148,400 shares of the company traded hands, compared to its average volume of 234,139. Karyopharm Therapeutics has a 1-year low of $7.48 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. analysts forecast that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.

In related news, insider Sharon Shacham sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $10.39, for a total transaction of $103,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total transaction of $55,777.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,340 shares of company stock valued at $255,380. 14.71% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Palo Alto Investors LLC grew its stake in shares of Karyopharm Therapeutics by 1.8% during the 2nd quarter. Palo Alto Investors LLC now owns 3,467,575 shares of the company’s stock worth $31,382,000 after acquiring an additional 61,100 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Karyopharm Therapeutics by 31.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after acquiring an additional 384,658 shares in the last quarter. Tekla Capital Management LLC grew its stake in shares of Karyopharm Therapeutics by 25.0% during the 2nd quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after acquiring an additional 151,455 shares in the last quarter. State Street Corp grew its stake in shares of Karyopharm Therapeutics by 10.1% during the 2nd quarter. State Street Corp now owns 511,920 shares of the company’s stock worth $4,631,000 after acquiring an additional 47,127 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Karyopharm Therapeutics by 16.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after buying an additional 72,000 shares during the last quarter. 60.92% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Analysts Give Karyopharm Therapeutics (KPTI) a $18.00 Price Target” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/12/cantor-fitzgerald-analysts-give-karyopharm-therapeutics-kpti-a-18-00-price-target.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.